Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Repligen
RGEN
Repligen
Expanding Dual Manufacturing And APAC Presence Will Drive Future Success
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 18 Analysts
Published
26 May 25
Updated
15 Aug 25
5
Set Fair Value
0
votes
Share
AnalystConsensusTarget
's Fair Value
US$179.72
30.6% undervalued
intrinsic discount
15 Aug
US$124.79
Loading
1Y
-15.0%
7D
0.4%
Author's Valuation
US$179.7
30.6% undervalued
intrinsic discount
AnalystConsensusTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystConsensusTarget Fair Value
US$179.7
30.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-14m
1b
2014
2017
2020
2023
2025
2026
2028
Revenue US$1.0b
Earnings US$140.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
14.38%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.33%
Calculation
US$140.05m
Earnings '28
x
90.43x
PE Ratio '28
=
US$12.66b
Market Cap '28
US$12.66b
Market Cap '28
/
57.02m
No. shares '28
=
US$222.12
Share Price '28
US$222.12
Share Price '28
Discounted to 2025 @ 7.33% p.a.
=
US$179.67
Fair Value '25